Evidence map›Paper›PMID 42470359›Full record

ReviewEpilepsia2026

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development.

Meir Bialer, Cecilie Johannessen Landmark, Matthias J Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H Steve White, Elaine Wirrell

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Epilepsia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Meir BialerInstitute for Drug Research, School of Pharmacy, Faculty of Medicine and David R. Bloom Center for Pharmacy, The Hebrew University of Jerusalem, Jerusalem, Israel.ORCID https://orcid.org/0000-0003-2046-4171
Cecilie Johannessen LandmarkDepartment of Pharmacy, Oslo Metropolitan University, The National Centre for Epilepsy, Member of the ERN EpiCare, Oslo, Norway.ORCID https://orcid.org/0000-0002-0877-8912
Matthias J KoeppResearch Department of Epilepsy, UCL Queen Square Institute of Neurology, London, UK.ORCID https://orcid.org/0000-0002-4277-8000
Emilio PeruccaEpilepsy Research Centre, Department of Medicine (Austin Health), The University of Melbourne, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0001-8703-223X
Piero PeruccaEpilepsy Research Centre, Department of Medicine (Austin Health), The University of Melbourne, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-7855-7066
Torbjörn TomsonDepartment of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.ORCID https://orcid.org/0000-0003-0554-5352
H Steve WhiteCenter for Epilepsy Drug Discovery, Department of Pharmacy, School of Pharmacy, University of Washington, Seattle, Washington, USA.ORCID https://orcid.org/0000-0003-4550-4408
Elaine WirrellDivisions of Child and Adolescent Neurology and Epilepsy, Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0003-3015-8282

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This article summarizes data for 13 investigational treatments for which at least preliminary seizure outcome data in patients with epilepsy were reported at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices held in Madrid, Spain, on May 3-6, 2026. The treatments reviewed include bexicaserin, a selective 5-hydroxytryptamine (5-HT, serotonin) type 2C (5-HT

Indexed as

AnticonvulsantsDrug DevelopmentEpilepsyAnimalsHumansAnticonvulsantsantiseizure medicationsbexicaserinBMB‐101drug developmentdrug‐resistant epilepsyelsunersenEPX‐100ES‐481ETX‐101PrevEp‐006 (seletracetam)radiprodilRAP‐219relutrigineStaccato Alprazolamvormatriginezorevunersen

Identifiers

PMID42470359
PMCPMC13675777

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.